Capricor Therapeutics Inc... (CAPR)

In the past week, Capricor Therapeutics reported Q2 2026 results showing a net loss of US$40.73 million and higher per-share losses, while also facing growing legal and regulatory scrutiny over its le...

Cantor Fitzgerald upgraded Capricor to ‘Overweight’ from ‘Neutral’ and raised its price target to $28 from $3.50, just weeks after the firm slashed its price target to $3.50 from $62.

The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.

Despite an advisory committee vote against deramiocel for cardiomyopathy, Capricor is pivoting to an upper limb indication with a strong cash position and promising HOPE-3 data.

CEO Marbán said Capricor remains focused on delivering the therapy to patients and is working closely with the FDA on a path forward centered on improvements in upper-limb skeletal muscle function dem...